| P50 | author | Armando Santoro | Q56335956 |
| | Riccardo Rosati | Q57655362 |
| | Marina Baretti | Q61151248 |
| | Nicola Personeni | Q38524333 |
| | Lorenza Rimassa | Q38524354 |
| P2093 | author name string | Maria Chiara Tronconi | |
| | Uberto Fumagalli Romario | |
| | Massimo Roncalli | |
| | Laura Giordano | |
| | Luca Rubino | |
| | Paola Spaggiari | |
| | Silvia Bozzarelli | |
| P2860 | cites work | Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. | Q54559293 |
| | HER-2 amplification is highly homogenous in gastric cancer. | Q54709456 |
| | Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. | Q54784542 |
| | Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas | Q60056779 |
| | Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study | Q80206188 |
| | Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections | Q82547098 |
| | Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status | Q87492670 |
| | Chemotherapy for advanced gastric cancer | Q24236634 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | HER2 testing in gastric cancer: a practical approach | Q28256814 |
| | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 |
| | Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients | Q33390513 |
| | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data | Q34019589 |
| | Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 |
| | Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial | Q34627996 |
| | Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 |
| | Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34656353 |
| | Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also | Q35610564 |
| | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 |
| | Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer | Q35809752 |
| | Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China | Q36153084 |
| | Her2/neu testing in gastric cancer: evaluating the risk of sampling errors | Q36615782 |
| | Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer | Q36778082 |
| | Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial | Q36950483 |
| | Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 |
| | Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy | Q37180708 |
| | Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge | Q37777021 |
| | Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? | Q37832986 |
| | Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Q43712233 |
| | Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. | Q44354605 |
| | Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. | Q50999355 |
| | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 |
| | Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). | Q53179955 |
| | Esophageal and esophagogastric junction cancers, version 1.2015. | Q53612616 |
| | Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. | Q54483761 |
| P433 | issue | 3 | |
| P921 | main subject | gastroesophageal adenocarcinoma | Q61913383 |
| P304 | page(s) | 428-437 | |
| P577 | publication date | 2016-08-16 | |
| P1433 | published in | Gastric Cancer | Q15724608 |
| P1476 | title | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications | |
| P478 | volume | 20 | |